Laman UtamaTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
Tutup sebelumnya
$3.70
Julat hari
$3.58 - $4.07
Julat tahun
$3.03 - $14.80
Permodalan pasaran
3.47J USD
Bilangan Purata
23.01K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Berita pasaran
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | — | — |
Perbelanjaan pengendalian | 666.00K | -53.88% |
Pendapatan bersih | -790.00K | 59.90% |
Margin untung bersih | — | — |
Pendapatan bagi setiap syer | — | — |
EBITDA | -666.00K | 65.46% |
Kadar cukai berkesan | — | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 2.83J | -58.12% |
Jumlah aset | 2.92J | -63.85% |
Jumlah liabiliti | 483.00K | -66.55% |
Jumlah ekuiti | 2.44J | — |
Syer tertunggak | 914.23K | — |
Harga kepada buku | 1.39 | — |
Pulangan pada aset | -51.03% | — |
Pulangan pada modal | -58.72% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -790.00K | 59.90% |
Tunai daripada operasi | -506.00K | 77.47% |
Tunai daripada pelaburan | — | — |
Tunai daripada pembiayaan | -62.00K | -115.27% |
Perubahan bersih dalam tunai | -568.00K | 57.49% |
Aliran tunai bebas | -193.25K | 80.89% |
Perihal
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Diasaskan
1991
Ibu pejabat
Tapak web
Pekerja
4
